Clinical Research Directory

Inclusion Criteria: 1. Adult patients = 18 years = 70 years of age. 2. ECOG 0-1 (Appendix A: Eastern Cooperative Oncology Group Performance Status Scale) with an estimated life expectancy of \> 6 months 3. Histologically confirmed unresectable or stage IV melanoma as per AJCC 8th edition. Unresectable melanoma is defined where the lesions are deemed to be unresectable by the treating surgeon. 4. Metastatic melanoma with at least 1 surgically accessible metastatic lesion (or aggregate lesions) with an estimated minimum diameter of = 1.5 cm 5. Measurable disease per RECIST 1.1 criteria (in addition to the resected lesion). 6. At least one anti-PD1 containing line of systemic therapy for unresectable or metastatic melanoma. Alternatively, one prior line of an adjuvant or neoadjuvant anti-PD1 containing regimen and all related adverse events have either returned to baseline or stabilized. Exclusion Criteria: 1. Life expectancy of less than 3 months. 2. Metastatic uveal melanoma. 3. Requirement for immunosuppressive doses of systemic corticosteroids (\>10 mg/day prednisone or equivalent) or other immunosuppressive drugs (e.g. mycophenolate, infliximab, or others) within the last 3 weeks prior to patient screening. Participants receiving steroids as replacement therapy for adrenocortical insufficiency at =10 mg/day of prednisone or another steroid equivalent dose are acceptable. 4. Participant has symptomatic untreated brain metastases. * A participant with historically treated brain metastases (ie, treatment was completed \>60 days prior to consenting for study participation) may be considered for study participation if the participant is clinically and radiologically stable for = 60 days * Participants with previously known asymptomatic brain metastases who do not clinically require treatment may be enrolled. 5. More than three melanoma brain metastases or evidence of leptomeningeal disease Other protocol defined exclusion criteria could apply.